#USA #San Francisco #Hagens Berman #Replimune #RP1

Replimune's Legal Troubles Post FDA Setback

In a striking turn of events, Replimune Group, Inc. (NASDAQ: REPL) finds itself facing a class action lawsuit following a devastating decision from the U.S. Food and Drug Administration (FDA). The lawsuit, filed by the prominent law firm Hagens Berman, alleges that the company misled its investors by exaggerating the potential success of its leading cancer therapy, RP1. The lawsuit highlights serious concerns about the integrity of Replimune's clinical trial data, particularly following the FDA's issuance of a Complete Response Letter (CRL) on July 22, 2025.

The Impact of the FDA's CRL

The FDA's CRL effectively denied approval of RP1 for treating advanced melanoma, prompting a catastrophic sell-off; Replimune's stock price plummeted by an astonishing 77% within a single day. This precipitated a loss of billions in market capitalization and left many investors scrambling for answers. The lawsuit claims that the company’s prior communications painted an overly optimistic picture of RP1's approval chances, misleading investors against the backdrop of the deteriorating clinical data.

Allegations of Misrepresentation

The complaint, titled Jboor v. Replimune Group, Inc., focuses on a class of investors who bought Replimune stocks between November 22, 2024, and July 21, 2025. According to the lawsuit, Replimune failed to openly communicate that:

• - There were significant doubts about the success rates in the IGNYTE trial.
• - The FDA was likely to view the data from this trial as inadequate for approval due to fundamental design flaws.
• - Issues like a heterogeneous patient population affected the interpretability of clinical results, significantly undermining the confidence investors had in the trial's findings.

Such allegations suggest that the trial was not as robust as Replimune led its investors to believe, contributing to the dramatic decline in stock value following the FDA's announcement.

Hagens Berman's Investigation

In light of these developments, Hagens Berman has launched an investigation into Replimune to determine whether the executives had prior knowledge of the trial’s deficiencies and chose to withhold such critical information from shareholders. The firm's analysis indicates that the flaws cited by the FDA were serious, not minor technicalities, and that they impact the results' overall credibility.

Hagens Berman noted, "Our focus is on understanding the basis of the FDA's rejection. The letter asserted that the trial lacked proper design and was hampered by issues such as patient diversity. These are not trivial matters; they are central to the data’s integrity and could have dramatically influenced investors' decisions."

The Call for Action

Investors who may have incurred substantial losses due to the steep stock decline are encouraged to come forward and participate in the ongoing litigation. Hagens Berman is specifically seeking individuals who can provide insights or documentation related to their investments in Replimune.

Moreover, the law firm is calling on potential whistleblowers with non-public details about Replimune to consider assisting in the investigation. According to SEC regulations, whistleblowers providing vital information may receive rewards up to 30% of any successful recoveries made by the agency. Those interested can contact Hagens Berman directly for further assistance and details regarding the case.

Conclusion

As this legal battle unfolds, it serves as a pivotal moment for Replimune and highlights the crucial importance of transparency and communication within the biotech sector. Investors remain vigilant as they await further developments in this high-stakes case, emphasizing the need for corporate accountability in regards to shareholder interests.